This clinical trial aimed to evaluate the safety and efficacy of oral treprostinil in subjects with pulmonary hypertension associated with pulmonary fibrosis. The study was designed as a multicenter, randomized, open-label trial involving at least 10 clinical trial centers and aimed to enroll 52 subjects over a 24-month period.